Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hepatitis C 4Carcinoma, Hepatocellular 3Respiratory Tract Infections 2Leukemia, Myeloid, Acute 2Respiratory Syncytial Virus Infections 1Recurrence 1Pneumonia 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Liver Diseases 1Infections 1Hepatitis 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1Bronchiolitis Obliterans Syndrome 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × Ribavirin × Clear all
NCT02308241 2023-01-05

Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies

Memorial Sloan Kettering Cancer Center

Phase NA Completed
12 enrolled 9 charts

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡